Sudden death of a horse with supraventricular tachycardia following oral administration of flecainide acetate.

This study details the sudden death of a horse due to supraventricular tachycardia after being given flecainide acetate. The horse, suffering from chronic heart arrhythmia, was previously treated with other medications, but the addition of flecainide resulted in critical cardiac complications and ultimately, death.

Study Approach

• This research delves into a particular case of an 8-year-old Hanoverian warmblood gelding treated for persistent supraventricular tachycardia – a type of heartbeat disorder.
• The horse had been previously administered other medications, including digoxin, procainamide hydrochloride, and quinidine sulfate, to tame the disorder.
• In an attempt to regulate heartbeat, the horse was orally given flecainide acetate following the unsatisfactory response to prior treatments.
• Instead of improving the condition, the administration of flecainide caused severe polymorphic ventricular tachycardia (a certain type of heart rhythm disorder) and ventricular fibrillation (a severe heart rhythm disorder), leading to sudden cardiovascular collapse and death.

Key Findings

• In horses, atrial fibrillation is often linked with poor performance, while the diagnosis of atrial tachycardia is relatively rare.
• In this particular case, the horse was suffering from atrial tachycardia, and the administration of flecainide acetate precipitated its death – a correlation not often observed.
• This case report adds new information about the potential danger of using flecainide acetate in horses undergoing cardiac dysrhythmias treatment and raises awareness about the possible complications of this medication.
• The study’s results point toward extreme caution when prescribing flecainide alone or in combination with other drugs for horses with heart rhythm anomalies.

Conclusions

• This case study provides veterinarians and equine medical practitioners with crucial information about the potential risks involved when administering flecainide acetate to manage cardiac dysrhythmias in horses.
• The reported death illustrates a potential adverse reaction that can occur when administering flecainide acetate, necessitating the careful consideration of its usage in equine treatments.
• This research reinforces the need for comprehensive clinical evaluation and close monitoring of the patient post medication to prevent such severe instances.